Last Update: Nov 15, 2024
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for the Treatment of Participants With Pulmonary Arterial Hypertension (Part B)
ClinicalTrials.gov Identifier:
Novartis Reference Number:CLTP001A12202
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

A study to learn about the treatment LTP001 in healthy participants (Part A) and in
participants with PAH (Part B) The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of
LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B)
followed by safety extension in participants with pulmonary arterial hypertension.

Healthy Volunteers, Pulmonary Arterial Hypertension
Phase1, Phase2
Recruiting
232
Oct 24, 2024
Sep 03, 2026
All
18 Years - (Adult, Older Adult)

Interventions

Drug

LTP

LTP001
Drug

Placebo

Placebo

Eligibility Criteria

Part A Inclusion Criteria:

- Healthy males and non-child-bearing potential females

Part A Exclusion Criteria:

- Clinically significant ECG or cardiac abnormalities, any surgical or medical
condition which might significantly alter the absorption, distribution, metabolism,
or excretion of drugs, or which may jeopardize the participant in the study Other
protocol-defined inclusion/exclusion criteria may apply.

Part B Inclusion Criteria:

-Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with
stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450
m.

Part B Exclusion Criteria:

Any surgical or medical condition which may place the participant at higher risk from
his/her participation in the study Women of child-bearing potential unless they are using
highly effective methods of contraception Sexually active males unwilling to use a condom
during intercourse while taking study treatment and for 24 hours after stopping study
treatment.

History of hypersensitivity to any of the study treatments or excipients

Other protocol-defined inclusion / exclusion criteria may apply

PPD Development LP

Recruiting

Austin,Texas,78744,United States

Craig Boyle

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals